Takeda and Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival ...
11 hrs ago | me-newswire.net
xml encoding="UTF-8"> ( BUSINESS WIRE )-- Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced data from a post-hoc analysis examining progression-free survival (PFS)...
Read more...
ADCETRIS relapsed Progression-free refractory HL Takeda sALCL post-ASCT patient examining survival therapy analysis post-hoc prior lymphoma PFS Seattle systemic